Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Portage Biotech Inc. (PRTG) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2024 | 39 K | -4,981,000 | 4.45 M | 7.78 M | 7.7 M |
| 2023 | 682 K | -10,545,000 | 23.73 M | 99.13 M | 13.68 M |
| 2022 | 209 K | -23,352,000 | 29.23 M | 194.66 M | 24.83 M |
| 2021 | -2,620,000 | 27.26 M | 174.86 M | 4.95 M | |
| 2020 | 560 K | 509 K | 27.53 M | 173.17 M | 3.79 M |